These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18336617)

  • 21. [The role of immunotherapy in metastatic cancer of the kidney].
    Thiounn N
    J Urol (Paris); 1994; 100(5):231-7. PubMed ID: 7730669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer.
    Sharma R; Hook J; Kumar M; Gabra H
    Eur J Cancer; 2008 Jan; 44(2):251-6. PubMed ID: 18155897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between emergency presentation, systemic inflammatory response, and cancer-specific survival in patients undergoing potentially curative surgery for colon cancer.
    Crozier JE; Leitch EF; McKee RF; Anderson JH; Horgan PG; McMillan DC
    Am J Surg; 2009 Apr; 197(4):544-9. PubMed ID: 18614139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    Rosenberg SA; White DE
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer.
    Canna K; McArdle PA; McMillan DC; McNicol AM; Smith GW; McKee RF; McArdle CS
    Br J Cancer; 2005 Feb; 92(4):651-4. PubMed ID: 15700032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation.
    Peccatori J; Barkholt L; Demirer T; Sormani MP; Bruzzi P; Ciceri F; Zambelli A; Da Prada GA; Pedrazzoli P; Siena S; Massenkeil G; Martino R; Lenhoff S; Corradini P; Rosti G; Ringden O; Bregni M; Niederwieser D;
    Cancer; 2005 Nov; 104(10):2099-103. PubMed ID: 16220555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous cardiac output and hemodynamic monitoring: high temporal correlation between plasma TNF-alpha and hemodynamic changes during a sepsis-like state in cancer immunotherapy.
    Caorsi C; Quintana E; Valdés S; Muñoz C
    J Endotoxin Res; 2003; 9(2):91-5. PubMed ID: 12803881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.
    Crumley AB; Stuart RC; McKernan M; McDonald AC; McMillan DC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e325-9. PubMed ID: 17645468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma.
    Sahasrabudhe DM; deKernion JB; Pontes JE; Ryan DM; O'Donnell RW; Marquis DM; Mudholkar GS; McCune CS
    J Biol Response Mod; 1986 Dec; 5(6):581-94. PubMed ID: 3491881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of immunological parameters on the effectiveness of systemic and loco-regional immunotherapy in disseminated renal carcinoma].
    Granov AM; Molchanov OE; Karelin MI; Shkol'nik MI; Krotova OA
    Vopr Onkol; 2009; 55(5):580-5. PubMed ID: 20020653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
    Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
    Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
    Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
    Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
    Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting.
    Bregni M; Bernardi M; Servida P; Pescarollo A; Crocchiolo R; Treppiedi E; Corradini P; Ciceri F; Peccatori J
    Bone Marrow Transplant; 2009 Aug; 44(4):237-42. PubMed ID: 19234510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma.
    Viey E; Laplace C; Escudier B
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):973-86. PubMed ID: 16336088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery.
    Samlowski WE; Majer M; Boucher KM; Shrieve AF; Dechet C; Jensen RL; Shrieve DC
    Cancer; 2008 Nov; 113(9):2539-48. PubMed ID: 18780316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
    Donskov F; Bennedsgaard KM; Von Der Maase H; Marcussen N; Fisker R; Jensen JJ; Naredi P; Hokland M
    Br J Cancer; 2002 Jul; 87(2):194-201. PubMed ID: 12107842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
    Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
    Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
    Vannier E; Kaser A; Atkins MB; Fantuzzi G; Dinarello CA; Mier JW; Tilg H
    Eur Cytokine Netw; 1999 Mar; 10(1):37-42. PubMed ID: 10210771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.